Literature DB >> 33983580

Single Cell Genomics for Tumor Heterogeneity.

Hae-Ock Lee1, Woong-Yang Park2.   

Abstract

Single cell genomics became a universal and powerful tool to study cellular diversity at genomic levels in normal and disease conditions. Cancer is a disease of genomic instability which instigates clonal evolution and intra-tumoral heterogeneity. Cancer progression also accompanies gross alterations in the microenvironment, and the stromal or immune cell types comprising the tumor microenvironment can be explored by single cell genomics. So far, breast cancer has been analyzed by single cell genomic tools for the clonal evolution, inter- and intra-tumoral heterogeneity in molecular signatures, and tumor microenvironment. We will briefly go over those studies and discuss the potential application of single cell genomics for the diagnostics and management of cancer.

Entities:  

Keywords:  Breast cancer; Single cell genomics; Treatment resistance; Tumor evolution; Tumor heterogeneity

Mesh:

Year:  2021        PMID: 33983580     DOI: 10.1007/978-981-32-9620-6_10

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  60 in total

1.  Tumor Heterogeneity--A 'Contemporary Concept' Founded on Historical Insights and Predictions.

Authors:  Danny R Welch
Journal:  Cancer Res       Date:  2016-01-03       Impact factor: 12.701

Review 2.  Precision Oncology: Who, How, What, When, and When Not?

Authors:  Lee Schwartzberg; Edward S Kim; David Liu; Deborah Schrag
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

Review 3.  Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future.

Authors:  Nicholas McGranahan; Charles Swanton
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

4.  [A. I. Karandash--the 1st sister of mercy].

Authors:  D P D'iachenko
Journal:  Med Sestra       Date:  1985-08

Review 5.  Biological subtypes of breast cancer: Prognostic and therapeutic implications.

Authors:  Ozlem Yersal; Sabri Barutca
Journal:  World J Clin Oncol       Date:  2014-08-10

6.  Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

Authors:  W Shi; T Jiang; P Nuciforo; C Hatzis; E Holmes; N Harbeck; C Sotiriou; L Peña; S Loi; D D Rosa; S Chia; A Wardley; T Ueno; J Rossari; H Eidtmann; A Armour; M Piccart-Gebhart; D L Rimm; J Baselga; L Pusztai
Journal:  Ann Oncol       Date:  2017-01-01       Impact factor: 32.976

7.  Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.

Authors:  A Goldhirsch; J N Ingle; R D Gelber; A S Coates; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2009-06-17       Impact factor: 32.976

8.  Activating ESR1 mutations in hormone-resistant metastatic breast cancer.

Authors:  Dan R Robinson; Yi-Mi Wu; Pankaj Vats; Fengyun Su; Robert J Lonigro; Xuhong Cao; Shanker Kalyana-Sundaram; Rui Wang; Yu Ning; Lynda Hodges; Amy Gursky; Javed Siddiqui; Scott A Tomlins; Sameek Roychowdhury; Kenneth J Pienta; Scott Y Kim; J Scott Roberts; James M Rae; Catherine H Van Poznak; Daniel F Hayes; Rashmi Chugh; Lakshmi P Kunju; Moshe Talpaz; Anne F Schott; Arul M Chinnaiyan
Journal:  Nat Genet       Date:  2013-11-03       Impact factor: 38.330

Review 9.  Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer.

Authors:  M S N Mohd Sharial; J Crown; B T Hennessy
Journal:  Ann Oncol       Date:  2012-08-02       Impact factor: 32.976

10.  Mutational landscape and significance across 12 major cancer types.

Authors:  Cyriac Kandoth; Michael D McLellan; Fabio Vandin; Kai Ye; Beifang Niu; Charles Lu; Mingchao Xie; Qunyuan Zhang; Joshua F McMichael; Matthew A Wyczalkowski; Mark D M Leiserson; Christopher A Miller; John S Welch; Matthew J Walter; Michael C Wendl; Timothy J Ley; Richard K Wilson; Benjamin J Raphael; Li Ding
Journal:  Nature       Date:  2013-10-17       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.